Molecular diagnostic of cytomegalovirus, Epstein Barr virus and Herpes virus 6 infections among blood donors by multiplex real-time PCR in Ouagadougou, Burkina Faso

Molecular diagnostic of cytomegalovirus, Epstein Barr virus and Herpes virus 6 infections among blood donors by multiplex real-time PCR in Ouagadougou, Burkina Faso

Lassina Traore¹, Issoufou Tao¹, Cyrille Bisseye^1,2, Birama Diarra¹, Tegwindé Rebeca Compaore¹, Yacouba Nebie³, Maleki Asshi¹, Alice Ouedraogo¹, Theodora Zohoncon¹, Florencia Djigma¹, Djénéba Ouermi¹, Nicolas Barro³, Mahamoudou Sanou³, Rasmata Traore Ouedraogo³, Jacques Simpore¹

 

¹Biomolecular Research Center Pietro Annigoni Labiogene,UFR / SVT, University of Ouagadougou BP 364 Ouagadougou, Burkina Faso, ²Laboratory of Molecular and Cellular Biology,University of Sciences and Techniques of Masuku, P 943 Franceville,Gabon, ³Molecular Biology, Epidemiology and Monitoring of Communicable of Bacteria and Viruses Through Food,UFR / SVT,University of Ouagadougou, Burkina Faso

 

 

^&Corresponding author
Cyrille Bisseye, Biomolecular Research Center Pietro Annigoni Labiogene ,UFR / SVT, University of Ouagadougou BP 364 Ouagadougou, Burkina Faso

 

 

 

 

In Burkina Faso, as in most developing countries, Cytomegalovirus (CMV), Epstein Barr virus (EBV) and Herpes virus 6 (HHV-6) are not diagnosed in blood donors [1]. CMV, EBV and HHV-6 infections are transmitted through blood and remain a significant cause of mortality and morbidity, especially in immunocompromised persons [2, 3]. Gastrointestinal CMV infections are extremely common in immunosuppressed patients [4]. CMV infection has been considered an important resistance factor to therapy in patients with intestinal inflammation, taking antiviral therapy [5, 6]. CMV infection of the intestine is clinically significant but not always with the classic cytopathic viral changes [7]. Congenital CMV infection is cited as the most important cause of infectious diseases of the central nervous system and hearing loss in children. It also endangers human fetus development; this issue makes the development of new strategies to prevent the acquisition and transmission of CMV a priority [8, 9]. EBV is one of the most common human viruses and is found throughout the world. It has been reported that 90% of adults are asymptomatic carriers. In immunocompromised individuals, the virus is activated and becomes an oncogene. EBV early infection has been described in children in Africa but also in developed countries where the primary infection is delayed until adulthood [10-12]. HHV6 is a virus similar to CMV; its discovery dates back to1986. It spread on the pandemic mode as CMV and EBV. An estimated of 80 to 90% is the number of people carrying the HHV-6 intermittently in their saliva [13, 14]. These three viruses are responsible for asymptomatic infections in immunocompetent individuals. In fact they cause disease especially in patients whose immune systems have been weakened, such as those treated with immunosuppressors, those affected by the human immunodeficiency virus (HIV) [15] and pregnant women. These viruses are responsible for many cancers, including Burkit's lymphoma (BL) observed endemic among African children [16], the nasopharynx lymphoma [17], B and T cells lymphomas [11, 18]. These types of cancers called non-Hodgkin represent the third type of cancer in sub-Saharan Africa, after breast and cervical cancers [19]. The objective of this study was to determine the prevalence of these three viruses in blood donors of the Regional Blood Transfusion Centre of Ouagadougou (CRTSO).

 

 

Sampling: this cross-sectional study was conducted in february 2012 at the National Blood Transfusion Centre of Ouagadougou in Burkina Faso. Two hundred (200) apparently healthy individuals aged ≤17 years with a weight >50 kg were recruited for blood donation. All donors answered questions intending to exclude individuals having signs of hepatitis, pregnant women and people having experienced high-risk sexual behaviour within 2 weeks preceding the intended donation.

 

DNA extraction and amplification of CMV, EBV and HHV-6: the genomic DNA of the viruses was extracted by using the extraction commercial kit DNA-Sorb-B (Sacace Biotechnologies, Como, Italy) following the manufacturer´s instructions. The amplification of CMV, EBV and HHV-6 was made by multiplex real time PCR using the amplification kit CMV / EBV / HHV-6 as Real-TM (Sacace Biotechnology, Italy) with the SaCycler-96 Real-Time PCR V.7.3 (Sacace Biotechnology, Como, Italy).

 

Statistical analysis: statistical analyses were performed with the software EpiInfo version 6 and SPSS version 17. P values ≤0.05 were considered significant.

 

Ethical considerations: free and informed consent of participants was obtained. This study received the approval of the institutional review board of the Biomolecular Research Center Pietro Annigoni (CERBA/ LABIOGENE)

 

 

Our study population consisted of 198 blood donors of which 17.7% were women and 82.3% were men. The donors' age ranged between 18 and 56 years with an average of 24.24 ± 6.69 years. More than three quarters (78.3%) of blood donors were from urban areas. The three herpes viruses: EBV, CMV and HHV-6 were diagnosed among blood donors in this study. Of the 198 blood donors tested 18 (9.1%) were positive for at least one of the three viruses. The prevalence of EBV, HHV-6 and CMV was respectively 5.1%; 6.1% and 5.1% (Table 1). No co-infection between EBV / CMV, EBV / CMV and HHV-6 / HHV-6 was observed in this study. While the triple infection EBV / CMV / HHV-6 concerned 3.5% (7/198) of the blood donors. The presence of CMV, EBV and HHV-6 was observed only in blood donors younger than 30 years. A single case of infection with HHV-6 was observed among those aged over 30 years (Table 2). The prevalence of EBV (8, 6% versus 4.3%), CMV (8.6% versus 3.4%) and HHV6 (11.4% versus 4.9%) was higher, respectively in women compared to men, but the observed difference was not statistically significant (Table 2). We did not observe significant differences by comparing the prevalence of human herpes virus between urban and rural areas. However, the prevalence of EBV and CMV was slightly higher in urban than rural areas respectively (5.8% vs 2.3% and 5.2% vs 4.7%); while that of HHV-6 was slightly higher in rural than in urban areas (7.0% vs 5.8%) (Table 2).

 

 

We show in this study that the overall prevalence of human herpes virus in blood donors was 9.1%. The prevalence of EBV, HHV-6 and CMV was respectively 5.1%; 6.1% and 5.1%. The prevalence of EBV (5.1%) observed in this study among blood donors is similar to the prevalence of 5.4% reported by Tao et al. (2013) [20] on blood donors in the city of Ouagadougou; but is well below the EBV seroprevalence of 20.0% obtained from the study on blood donors from Ghana by Adjei et al. [2] In this study, the prevalence of 5.1% reported in CMV blood donors corroborates the results of 4.3% obtained by Furui et al. in Japan, in 2013 [21]. However, it is lower than the anti-IgG and anti-IgM seroprevalence of 92.2% and 12.2% respectively, observed in Ouagadougou among blood donors [1]. The seroprevalence we obtained from our study is also less than the anti IgG seroprevalence reported by Kothari and al. India in 2002 [22] and by Adjei et al. Ghana in 2006 [23]; who had found a prevalence of 95.0% and 93.3%; respectively. Nevertheless, it remains below the anti-IgM seroprevalence of 0.07% reported by Kumar et al. in 2008, in India. [24] Discrepancies between our results and those of previous studies could be explained by the diagnostic techniques (molecular in our study versus serological in previous studies). Almost all cases of infection with human herpes viruses was observed in blood donors younger than 30 years. Our results are consistent with a previous study which reported that EBV infections, CMV and HHV-6 are more common in young individuals [21, 25, 26]. In our study, we obtained the prevalences of 5.1%; 6.1% and 5.1% respectively for EBV, HHV-6 and CMV, and the EBV infection triple / CMV / HHV-6 concerned 3.5% (7/198) of blood donors. This result is similar to that of Wang et al. in 2010, in China [26] who also reported a rate of 63.6% for EBV / CMV coinfection, with the prevalence of 68.9%, 81.3% for EBV and CMV. Despite the limited sample size, the analysis allows us to report for the first time the prevalence of EBV, CMV and HHV6 in blood donors in Burkina Faso. From the prevalence obtained, we recommend the diagnosis of herpes viruses in all blood donors in order to reduce at best their transmission by blood transfusion.

 

 

This study also reports for the first time, the prevalence of CMV and HHV-6 in Ouagadougou blood donors. A study on a larger sample and including other regions is needed to establish the prevalence of the human herpes viruses in Burkina Faso.

 

 

The authors declare no conflicts of interest

 

 

Study design: Cyrille Bisseye, Nicolas Barro, Rasmata Traore/Ouedraogoand Jacques Simpore. Sampling: Issoufou Tao, Lassina Traoré and Cyrille Bisseye. Samples processing : Lassina Traoré, Issoufou Tao, Birama Dirra, Maleki Asshi, Alice Rogomenoma Ouedraogo, Theodora Zohoncon, Yacouba K. Nebié and Cyrille Bisseye. Analysis and data interpretation: Lassina Traoré, Issoufou Tao, Mahamoudou Sanou, Florencia Djigma, Djeneba Ouermi and Cyrille Bisseye. Manuscript drafting and corrections: Lassina Traoré, Issoufou Tao, Birama Diarra, Tegwindé Rebeca Compaoré, Florencia Djigma, Cyrille Bisseye and Jacques Simpore

 

 

The authors thank the staff of the National Blood Transfusion Center, the Saint Camille medical center and CERBA. They express their deep gratitude to the Italian Episcopal Conference (CEI) and WAEMU (through its PACER 2 program) for their financial support.

 

 

Table 1: prevalence of EBV, CMV and HHV-6 in blood donors

Table 2: infection with CMV, EBV and HHV- 6 as a function of the age, sex and place of blood donation

 

 

1. Ouedraogo AS, Yameogo JT, Poda GE, Kientega Y, Ouedraogo Traore R. Prevalence of anti-CMV antibodies in blood donors in Ouagadougou (Burkina Faso). Med Sante Trop. 2012 Jan-Mar;22(1):107-9. PubMed | Google Scholar


2. Adjei AA, Armah HB, Gbagbo F, Boamah I, Adu-Gyamfi C, Asare I. Seroprevalence of HHV-8, CMV, and EBV among the general population in Ghana, West Africa. BMC Infect Dis. 2008 Dec 5;382(1):28-36. PubMed | Google Scholar


3. Gandhi MK, Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis. 2004 Dec;4(12):725-38. PubMed | Google Scholar


4. Baroco AL, Oldfield EC. Gastrointestinal cytomegalovirus disease in the immunocompromised patient. Curr Gastroenterol Rep. 2008 Aug;10(4):409-16. PubMed | Google Scholar


5. Roblin X, Pillet S, Oussalah A, Berthelot P, Del Tedesco E, Phelip JM et al. Cytomegalovirus load in inflamed intestinal tissue is predictive of resistance to immunosuppressive therapy in ulcerative colitis. Am J Gastroenterol. 2008 Nov;106(11):2001-8. PubMed | Google Scholar


6. Domenech E, Vega R, Ojanguren I, Hernandez A, Garcia-Planella E, Bernal I et al. Cytomegalovirus infection in ulcerative colitis: a prospective, comparative study on prevalence and diagnostic strategy. Inflamm Bowel Dis. 2008 Oct;14(10):1373-9. PubMed | Google Scholar


7. Yan Z, Wang L, Dennis J, Doern C, Baker J, Park JY. Clinical Significance of Isolated Cytomegalovirus-Infected Gastrointestinal Cells. Int J Surg Pathol. 2014 Jun 2; 22(6):492-8. PubMed | Google Scholar


8. Sahiner F, Honca M, Cekmez Y, Kubar A, Honca T, Fidanci MK et al. The role of maternal screening in diagnosing congenital cytomegalovirus infections in highly immune populations. Ir J Med Sci. 2014 Jun 4;184(2):475-81. PubMed | Google Scholar


9. Hertel L. Human cytomegalovirus tropism for mucosal myeloid dendritic cells. Rev Med Virol. 2014 Nov;24(6):379-95. PubMed | Google Scholar


10. Biggar RJ, Henle W, Fleisher G, Bocker J, Lennette ET, Henle G. Primary Epstein-Barr virus infections in African infants I: decline of maternal antibodies and time of infection. Int J Cancer. 1978 Sep 15;22(3):239-43. PubMed | Google Scholar


11. Macsween KF, Crawford DH. Epstein-Barr virus-recent advances. Lancet Infect Dis. 2003 Mar;3(3):131-40. PubMed | Google Scholar


12. Sarmati L. HHV-8 infection in African children. Herpes. 2004 Aug;11(2):50-3. PubMed | Google Scholar


13. Salahuddin SZ, Ablashi DV, Markham PD, Josephs SF, Sturzenegger S, Kaplan M et al. Isolation of a new virus, HBLV, in patients with lymphoproliferative disorders. Science. 1986 Oct 31;234(4776):596-601. PubMed | Google Scholar


14. Di Luca D, Mirandola P, Ravaioli T, Bigoni B, Cassai E. Distribution of HHV-6 variants in human tissues. Infect Agents Dis. 1996 Oct;5(4):203-14. PubMed | Google Scholar


15. van Baarle D, Hovenkamp E, Callan MF, Wolthers KC, Kostense S, Tan LC et al. Dysfunctional Epstein-Barr virus (EBV)-specific CD8(+) T lymphocytes and increased EBV load in HIV-1 infected individuals progressing to AIDS-related non-Hodgkin lymphoma. Blood. 2001 Jul 1;98(1):146-55. PubMed | Google Scholar


16. Epstein MA, Achong BG, Barr YM. Virus Particles in Cultured Lymphoblasts from Burkitt's Lymphoma. Lancet. 1964 Mar 28;1(7335):702-3. PubMed | Google Scholar


17. Ferrari D, Codeca C, Bertuzzi C, Broggio F, Crepaldi F, Luciani A et al. Role of plasma EBV DNA levels in predicting recurrence of nasopharyngeal carcinoma in a Western population. BMC Cancer. 2012;12(1):208. PubMed | Google Scholar


18. Zhang T, Fu Q, Gao D, Ge L, Sun L, Zhai Q. EBV associated lymphomas in 2008 WHO classification. Pathol Res Pract. 2014 Feb;210(2):69-73. PubMed | Google Scholar


19. Dangou JM, Sambo BH, Moeti M, Diarra-Nama A-J. Cancer prevention and control in the WHO African region: a plea for action. J Afr Cancer. 2009;1(1):56-60. PubMed | Google Scholar


20. Tao I, Bisseye C, Nagalo BM, Sanou M, Kiba A, Surat G et al. Screening of Hepatitis G and Epstein-Barr Viruses Among Voluntary non Remunerated Blood Donors (VNRBD) in Burkina Faso, West Africa. Mediterr J Hematol Infect Dis. 2013;5(1):e2013053. PubMed | Google Scholar


21. Furui Y, Satake M, Hoshi Y, Uchida S, Suzuki K, Tadokoro K. Cytomegalovirus (CMV) seroprevalence in Japanese blood donors and high detection frequency of CMV DNA in elderly donors. Transfusion. 2013 Oct;53(10):2190-7. PubMed | Google Scholar


22. Kothari A, Ramachandran VG, Gupta P, Singh B, Talwar V. Seroprevalence of cytomegalovirus among voluntary blood donors in Delhi, India. J Health Popul Nutr. 2002 Dec;20(4):348-51. PubMed | Google Scholar


23. Adjei A, Armah H, Narter-Olaga E. Seroprevalence of cytomegalovirus among some voluntary blood donors at the 37 military hospital, accra, ghana. Ghana Med J. 2006 Sep;40(3):99-104. PubMed | Google Scholar


24. Kumar H, Gupta PK, Kumar S, Sarkar RS. Is seroprevalence of anti-IGM CMV among blood donors relevant in India. Indian J Pathol Microbiol. 2008 Jul-Sep;51(3):351-2. PubMed | Google Scholar


25. Kabyemera R, Masalu N, Rambau P, Kamugisha E, Kidenya B, De Rossi A et al. Relationship between non-Hodgkin's lymphoma and blood levels of Epstein-Barr virus in children in north-western Tanzania: a case control study. BMC Pediatr. 2013;13:4. PubMed | Google Scholar


26. Wang X, Yang K, Wei C, Huang Y, Zhao D. Coinfection with EBV/CMV and other respiratory agents in children with suspected infectious mononucleosis. Virol J. 2010 Aug;21(2):251-64. PubMed | Google Scholar